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BACKGROUND: Current findings set a new understanding that every adult tissue has its own intrinsic progenitor or stem cell, give a potency 
for their innate turnover dynamics. This broke the old 
assumption that adult tissues cannot regenerate themselves. 
Localized tissue regeneration was regulatory oversight by a 
separate class of local cells originating as perivascular cells, 
suggested a profound influence on using specific cells for 
cell therapies as a health care delivery tool set.
CONTENT: The mesenchymal stem cells (MSCs) could 
be mobilized from the marrow or other depots or can be 
culture-expanded MSCs which are delivered to the damage 
site either by direct or systemic injection. MSCs act 
paracrine and autocrine by inducing a variety of cytokines 
and growth factors which suppress local immune system, 
inhibit fibrosis (scar formation) and apoptosis, enhance 
angiogenesis, and stimulate mitosis and differentiation of 
tissue, intrinsic reparative or stem cells. These referred a 
trophic effects, different from the direct differentiation of 
MSCs into repair tissue. Thus, MSC suggested as a multi-
drug delivery vehicles in response of injury. In this regard, 
the trophic effects of MSCs may have profound clinical use.
SUMMARY: Managing the body’s natural repair and 
regeneration capacities is the new frontier for modern 
medicine and the basis for the science of cell therapies. 
Study of MSCs become one avenue that being pursued to 
explore the endogenous tissue regeneration management, so 
that people have a great expectation to solve many severe 
diseases.
KEYWORDS: mesenchymal stromal/stem cell, paracrine 
or autocrine activities, trophic mediator, inflammation, 
wound healing
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Mesenchymal stem cells (MSCs), which also referred to 
as mesenchymal or multipotent stromal cells was first 
discovered in the bone marrow in early 1970s.(1) After more 
than 30 years of research and an ever increasing number 
of published reports, MSCs have been subsequently found 
in many tissues, such as umbilical cord blood, adipose, 
brain, liver, lungs (2-8) and are seen as promising cells 
for the treatment of a large variety of disorders, including 
cardiovascular,  neurodegenerative and autoimmune 
diseases (9,10). Several pre-clinical studies have been 
described the therapeutic potential of MSCs using various 
animal models of disease, with the latest investigations 
mostly focused intensely on mechanisms of effect. Three 
major functions of MSCs  have  been  associated  with 
their  therapeutic effects, those  are  tissue  replacement 
via  multipotent differentiation (11,12), immunomodulatory 
and anti-inflammatory effects (13,14) and the secretion 
of molecules that instigate or assist in tissue repair (i.e., 
paracrine activity) (15-17).
 Whether called mesenchymal stem cells, mesenchymal 
stromal cells, multipotent stromal cells, skeletal stem cells, 
or other names, this class of stem/progenitor cells has been 
continuously studied for more than two decades. More than 
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MSC as Medicinal Signaling Cell
30,000 publications about more than 300 clinical trials on 
over 10,000 subjects received either MSCs or MSC-like 
cells, started from two decades ago, and studies about the 
science of MSCs and their therapeutic potential were still 
going. MSCs safety records remains strong.(18)
 MSCs are defined by their capacity to differentiate 
to osteoblasts, chondroblasts and adipocytes, by plastic 
adherence and by a peculiar expression pattern of certain 
surface  proteins.(1,19) Firmly attracted to wounds, 
MSCs are mobilized  by injuries which they enter to 
modulate inflammatory   responses   and  stimulate   tissue 
regeneration.(20) MSCs  are  a  heterogeneous  population 
and  also  able  to  emerge  from  pericytes  or  endothelial 
cells (21), which  may  help to accelerate local MSC 
recruitment. MSCs were originally known to have role 
in tissue repair by trans-differentiating into cells, such as 
epithelial cells or neurons, which are required to restore 
the injured tissue.(22-25) However, later it became evident 
that their paracrine activities are more important for wound 
healing than their differentiation potential.(21,26-28) 
 It is important to understand that all adult stem cell 
systems exist to guarantee that when cells within tissues 
expire naturally, these cells can be expeditiously replaced 
to provide physiological balance in the organism. Every cell 
in the body has a lifespan ranging from 20 minutes to many 
years depending on the cell. Some circulating blood cells 
expire in 20 minutes after forming, while neurons exist for 
many years. The expiration allows the tissue to rejuvenate 
itself and provides it with a mechanism to slowly change its 
properties as a function of age and/or use. Hence, not only 
the stem cells are source of replacement parts for expired 
units, but they also serve as reserve cells for damaged or 
compromised adult tissues requiring more extensive repair, 
regeneration or expansion.(7,14,28) Caplan has suggested 
that the  acronym MSCs be retained for this class of cells, 
but that it should stand for medicinal signaling cells.(29) 
Clearly, the major function of MSCs in vivo is not as 
multipotent progenitor stem cells, but as cells that help to 
manage repair and/or regeneration at sites of injury.(30-33)
 The management of these composite trophic activities 
is an inherent capacity of MSCs independent of the tissue 
of origin. Each tissue houses MSCs/pericytes have different 
chemistries because of the local environments in which they 
are housed. The small amount of data now available suggests 
they all have the same sensory and response elements 
(immunomodulatory and trophic) even when expanded in 
culture under very different culture conditions.(34-37) If we 
analog these to the computer’s working components,  MSCs 
are used as the central connection in the broad theme, not as 
multipotent progenitors but rather as an important control 
element  in  the  natural local regeneration process,  and 
cells are  meant  to  draw several  important  scientific 
principles.(38)
The publication by Crisan, et al., is a landmark paper 
which presents a wide body of work that defines, refines, 
confirms, establishes and validates both the in situ and in 
vitro links between adult human MSCs and perivascular 
cells, summarily referred to here as pericytes.(39) Two 
important recent pieces of information strongly argue 
that Caplan should rename the MSCs. First, MSCs can be 
isolated from almost every tissue in human body, since all 
these tissues are vascularized and every vessel has MSC 
in abluminal locations. These perivascular cells can be 
summarily called pericytes.(40,41) This led us to suggest 
that ‘‘all MSCs are pericytes’’.(39) But the opposite, that 
all pericytes are MSCs, is not correct. Since some pericytes 
exhibit highly specialized characteristics and do not exhibit 
MSCs multipotency properties.(29) The second issue is that 
MSCs are being used therapeutically because they home 
to sites of inflammation  or  tissue  injury (42) and they 
secrete massive levels of bioactive agents that are both 
immunomodulatory (13) and trophic (43).
 The documentation that MSCs are derived from 
perivascular cells, pericytes (39,41), now explains how 
MSCs  can  be  isolated  from almost every tissue in the 
body (44,45). Moreover, the fact that MSCs have the 
ability to secrete immunomodulatory and trophic mediators 
strongly argues that their natural and normal in vivo 
function is as “medicinal signaling cells” for sites of injury 
or inflammation  in  all  of the tissues in which they are 
housed.(29,31) Today on the website clinicaltrials.gov a 
search using “mesenchymal stem cells” in the website’s 
search engine shows that over than 500 clinical trials are 
listed covering a surprisingly big array of clinical conditions, 
with most of these studies using either immunomodulatory 
or regenerative (trophic) aspects, or both, as the central 
components of MSCs’ therapeutic intention.
 The realization that MSCs are acquired from pericytes 
changes the context of considering how MSCs arise 
and function in vivo during the body’s response to both 
localized injury and the demand for regeneration/repair. 
Pericyte released in its simplest origin from its association 
with the basal lamina of the blood vessel where the injury 
or inflammation occurred, and sensing its surrounding 
milieu then responding by growing into MSC. It will 
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soon be activated and dynamically changes while keyed 
to the detailed chemistry of its niche. MSCs that have 
been activated put out a concentrated localized curtain of 
bioactive molecules that serves to inhibit the interrogating 
cells of the body’s overaggressive immune system.(46,47) 
This acts as the first-line defense against the autoimmune 
reactions which established due to injured tissue in the 
immediate region. Together with this curtain, MSC 
coordinately secretes molecules set up for regenerative (not 
repair) microenvironment.
 Thus, MSC thought to play a critical role by secreting 
some bioactive factors for mediating immune/inflammatory 
suppression and paracrine activity. Some proteomic studies 
have recently carried on for a deeper understanding about 
MSC potencies in clinical setting. Majority of these studies 
have utilized either shotgun broad range scanning or targeted 
proteomic approaches (i.e., candidate-based) to uncover 
soluble or extracellular vesicle (EV) bound factors present 
in MSC conditioned media (CM). A subset of investigations 
have conducted cell-free-based animal studies with MSC-
CM or CM-derived EVs (e.g., exosomes and microvesicles) 
to  further  show  the  therapeutic  relevance  of  their 
findings.(15)
 Some studies in rodents clearly shown a good results of 
MSC in promoting regeneration of damaged tissues without 
any significance engraftment (48,49), and these support the 
idea of MSC’s paracrine activity in mediating tissue repair 
by secretes bioactive molecules such as interleukins (IL) 
and tumor growth factors (TGF) that promote regenerative 
microenvirontment in the injury vicinity.(15,16,50,51) To 
date, therapeutic response of CM has been tested in disease 
models for lung injury (15), chronic kidney disease (50) and 
liver injury (16,51), among others, and demonstrate that 
MSC-CM alone is sufficient to mediate lasting therapeutic 
effects.
 It is evident from the current body of research 
that immune/inflammatory modulation and paracrine 
factors contained within the MSC secretome function in a 
cooperative manner to generate a tissue microenvironment 
that is more permissive of repair/regeneration. In the 
last decade, investigators have made progress towards 
characterizing CM and EVs derived from MSC. These studies 
have identified plenty candidate modulators of paracrine 
effects and cell-mediated/inflammatory suppression.(17) 
Taken together, the current body of research seems to argue 
that multipotent differentiation have minimal contribution 
in beneficial effects attributed to MSC while immune/
inflammatory suppression and paracrine activity have a 
more predominant role.
MSC as Thropic Mediator
MSCs can differentiate into bone, cartilage, muscle, marrow 
stroma, tendon-ligament, fat and other connective tissues. 
So, what do MSCs do naturally and where is the MSC niche? 
New insight and clinical experience proposes that MSCs are 
naturally found as perivascular cells, summarily referred to 
as pericytes, which are released at the sites of injury, where 
they secrete large quantities of bioactive factors that are both 
immunomodulatory and trophic such as growth factors, and 
cytokines that can suppress T cells activity.(52)
 Virtually, MSC presents in all tissue and interact 
with tissue cells and immune cells under the condition 
of inflammation. Due to their multipotent differentiation 
capacity, they can differentiate into osteoblasts, adipocytes, 
chondrocytes, etc., while with their immunomodulatory 
capacity they sense and control inflammation and modify 
the cytokines proliferation and expression in lymphocytes 
and myeloid-derived immune cells.(53)
 While it was originally predictable that MSCs could 
be used for replacement of dysfunctional cells through their 
capacity to differentiate into tissue cells (54), the current 
paradigm is that MSCs support resident progenitor cells via 
paracrine mechanisms (55,56). This idea may be even need 
refinement, as recent studies suggest that MSCs may not have 
a long lifespan after administration.(57,58) The reason why 
this may be the case is not clear. After administered, MSCs 
disappear rapidly, so this raise questions of how its work? 
Some suggestions think than a small fraction could escape 
from death then migrate into the injury or inflammation 
site for doing their work, or, they were indeed could pass 
on their beneficial effects in mediating tissue repair or 
immunomodulation very rapidly. Even the clean-up process 
of MSCs itself may be a trigger for the therapeutic effects of 
MSCs.(59)
 In all cases, it appears that MSCs do not differentiate 
into cardiac myocytes, meniscal cells or neurons. Instead, 
the MSCs exert their influence by the secretion of huge 
amounts of growth factors (stem cell factor (SCF), 
granulocyte-colony stimulating factor (G-CSF) and stromal 
cell-derived factor 1 (SDF-1)) and cytokines (IL-2, IL-
10) to affect a therapeutic outcome.  We call these effects 
‘trophic’ activity (14), named after this term that was 
related to neural effects (59). All of these models to have 
a common trophic mode of action of the MSCs: the MSCs 
secrete bioactive molecules that: (a) inhibit apoptosis and 
limit the field of damage or injury; (b) inhibit fibrosis or 
scarring at sites of injury; (c) stimulate angiogenesis and 
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MSC as Injury Drug-Store
bring in a new blood supply; and (d) stimulate the mitosis 
of tissue-specific and tissue-intrinsic progenitors, such as 
cardiac or neural stem cells.(14) The immunomodulation 
inhibits lymphocyte surveillance of the injured tissue, thus 
preventing autoimmunity, and allows allogeneic MSCs 
to be used in a variety of clinical situations. Thus, a new, 
enlightened era of experimentation and clinical trials has 
been initiated with xenogenic and allogeneic MSCs.
 The bioactive molecules secreted from MSCs work 
either directly by promote intracellular signaling, indirectly 
by induce vicinity cells to secrete the functionally active 
agents, or even both. The indirect effect of MSCs refers as 
trophic effect, consistent as neurobiology term to indicate 
the bioactive molecules released from nerve terminals that 
are  not  neurotransmitters.(60,61)  As  seen  in  Figure  1, 
MSCs can have two distinct functions. MSCs is able to 
provide replacement units for expired cells in mesenchymal 
tissues, and MSCs can have trophic effects on cells in their 
vicinity without creating newly differentiated mesenchymal 
phenotypes and, thus, also influence the regeneration of 
cells  or  tissues  by  purely  a  bioactive  factor  effect 
(Figure 2).(12)
 Studies documented the effects of transplanted MSCs 
expressing the pro-survival gene Akt1, and the scientists 
recognized that the molecules released by trans-planted 
MSCs are important.(62) The trophic effects of MSCs 
have been documented by Tang, et al., who showed that 
MSCs implanted into ischemic myocardium simulated an 
increased production of vascular endothelial growth factor 
(VEGF), increased vascular density and blood flow, and 
decreased apoptosis, all of which were likely influenced by 
the secretion of bioactive molecules.(63)
 However, the use of MSCs as site-regulated multidrug 
dispensers, especially allogeneic MSCs, opens avenues of 
therapy unimagined around 5-10 years ago. For example, 
uses of MSCs in asthma (64), radiation exposure (65), 
neurological disorders (65), etc., are now being explored. 
How to deliver a precise dose of MSC to be effective in 
Figure 1. The dual roles of MSCs. MSCs play a central role 
in aspects of tissue regeneration and repair, maintenance and 
turnover and the control of hematopoiesis in the bone marrow.(14) 
(Adapted with permission from Wiley-Liss).
their site of action and where is actually their main site, still 
become a challenge, since not all blood vessels or pericytes 
are the same. Similarly that MSCs from different source 
must be different in their responses and activities.(67,68) 
Are the MSCs from marrow better than the MSCs from fat, 
muscle or liver for a specific site relative to trophic activity or 
immunomodulation? Only time and a big amount of careful, 
quantitative data will help us answer these questions.
MSCs are the focal point of intensive efforts worldwide 
directed not only at elucidating their nature and unique 
properties, but also at developing cell-based therapies 
for a diverse range of diseases. More than three decade 
have passed since the original formulation of the concept, 
revolutionary at the time, that multiple connective tissues 
could emanate from a common progenitor or stem cell 
confined in the postnatal bone marrow. Despite the plentiful 
important advances made since that time, substantial 
ambiguities until plague the field regarding the nature, 
identity, function, mode of isolation and experimental 
handling of MSCs.(69)
 The idea that MSCs can exert functions other than 
those characteristics of a stem or progenitor cell, which is 
tissue regeneration, is conceptually intriguing and assuredly 
supported by direct evidence. One defining feature of 
bone marrow-derived MSCs is to establish, organize and 
transfer the hematopoietic microenvironment or niche in 
vivo.(1,40,70) In in vivo systems which can recapitulate the 
ontogeny of bone and marrow, this function is intertwined 
with the organization of nascent blood vessels into 
functional networks, which seems to be directed by MSCs 
through direct interaction with endothelial cells.(40) In 
other experimental systems that were not designed or suited 
to allow for the skeletogenic potential of MSCs to unfold, 
their ability to organize vascular networks can be portrayed 
even in isolation, meaning in the absence of bone or bone 
marrow.(71-73) Thus, at least with respect to hematopoietic 
cells (including hematopoietic stem cells) and endothelial 
cells, MSCs exert a function that is not immediately 
traceable to a general stem-cell property.
 It is now clear that isolated pericytes exhibit a panel 
of cell surface markers that are identical to those expressed 
by isolated MSCs.(74) Furthermore, a novel cell surface-
specific marker of adipose-derived stem cells, white adipose 
tissue (WAT)7, which corresponds to a cleavage product of 
decorin, is also expressed in vivo by perivascular cells that 
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exhibit typical pericyte markers such as β-type platelet-
derived growth factor receptor (PDGFR-b) and α-smooth 
muscle actin (aSMA).(75) These and other observations 
make it possible to speculate in a commentary in this journal 
that all MSCs are pericytes.(39) By knowing that all MSCs 
are indeed pericytes, the role of MSCs physiologically and 
therapeutically possibly can be visualized. In particular, if 
pericytes are the source of MSCs, what will be their local 
functions in the tissue microenvironment beyond their 
mesenchymal differentiation capabilities?
 Based on the examples described above, the model 
that MSCs are clinically active at different tissue sites, 
that MSCs are pericytes and can be isolated from any 
vascularized tissue, and that MSCs secrete huge quantities of 
a different type of bioactive molecules as part of their local 
trophic and immunomodulatory activities. Caplan propose 
that this specific MSC tissue ‘‘regulatory’’ phenotype arises 
as a consequence of broken or inflamed blood vessels at 
sites of tissue damage.(30) This model does not exclude the 
possibility that pericytes naturally have an on/off cycle in 
the non-injured situation.
 In keeping with this understanding, in cases of vessel 
damage, the injury will activate the pericytes release and 
then grow into MSCs, thereafter secreting a spectrum of 
bioactive molecules (i.e., drugs) which inhibit any immune 
cells to the tissue damage and also prevent autoimmune 
activities from developing. These bioactive molecules also 
establish a regenerative microenvironment to support the 
regeneration and refabrication of the injured tissue. In this 
context, the MSCs have role as site-regulated, multidrug 
dispensaries, or ‘‘drug-stores,’’ to promote and support the 
natural regeneration of focal injuries. If these injuries are 
large or occur in older individuals, the natural supply of 
MSCs  must  be  supplemented  by  local  or  systemic 
delivery.(30)
 MSCs are released from their perivascular location, 
then become activated, and establish a regenerative 
microenvironment by secreting bioactive molecules and 
regulating the local immune response. These trophic and 
immunomodulatory activities offer that MSCs may serve as 
site-regulated ‘‘drug-stores’’ in vivo.(30)
Figure 2. Trophic mechanism of tissue repair. MSCs have the 
capacity to trophically mediate hematopoiesis as a natural part of 
homeostasis.(14) HSC: Hematopoetic stem cell, (Adapted with 
permission from Wiley-Liss).
MSCs Manage Inflammation
We and other vertebrates are equipped to live in a sea of 
microorganisms. The reason we survive is because we 
have formidable inflammatory and immune response 
systems which protect us against external confrontations 
with microorganisms and internal confrontations with the 
bacteria in  our  intestinal flora that outnumber the cells in 
our bodies.(76,77) Fortunately, we have multiple systems in 
resolving and modulating inflammation. The systems include 
small molecules such as prostaglandins, lipoxins, protectins 
and resolvins.(78) They also include cellular phenotypes 
such  as  alternatively  activated M2 macrophages (79) 
and regulatory T cells (80,81). Recent reports indicate 
that additional important guardian cells for modulating 
inflammation are MSCs. The interest in the guardian role 
of MSCs is in part related to their presence as adventitial 
reticular cells that participate in normal wound repair and 
in regulation of hematopoietic cells in bone marrow.(82,83)
MSCs become very interesting because they were readily 
obtained from the patients, have lots of potential benefits, 
easily expanded by culture, and generally not tumorigenic.
 The first line of defense presents by the innate immune 
system against invading pathogens is in form of mechanical 
barriers, particularly the skin and mucous membranes. In 
addition to their protecting and cleansing functions, these 
barriers regulate local and systemic immune responses 
by inducing inflammation or tolerance.(84) MSCs reside 
in local epithelial niches in close proximity to capillary 
walls.(85,86) They might provide a life-long regenerative 
reservoir of new cells such as myofibroblasts (87), as well as 
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macrophages (102,131). This results in cells generation but 
unable to efficiently stimulate type I immune responses. 
In some evidences, such MSC-conditioned cells showed 
phenotypic and functional features of regulatory cells, 
capable of further supress even ongoing inflammatory/
immune responses. In the case of macrophages, MSCs 
can induce polarization towards M2 cells.(132) M2 cells 
represent the so called ‘alternatively activated’ macrophages, 
which not only have regulatory activity but also participate 
in wound healing.(133)
 Substantial advancement has been made recently 
in the understanding of the interactions between MSCs 
and immune cells. As a result of such studies, now MSCs 
are considered to intuitively respond to their immediate 
environment and to adapt their response accordingly through 
the release of soluble factors such as  PGE2, kyneurenine, 
IL-10, TNF-stimulated gene 6 protein  (TSG-6), NO, and 
transforming growth factor (TGF-b)-1 (134-139) and/
or through  cell  contact  signaling  such as  Notch, and 
CD95/Fas (140-142). This multifaceted responsiveness is in 
keeping with an arising understanding of the role of primary 
MSCs in regulating, together with macrophages and other 
cell  types,  the  bone  marrow stem hematopoietic cell 
niche.(143,144)
 MSCs are not constitutively immunosuppressive, 
they require a ‘licensing’ step provided by molecules of 
acute phase inflammation, like IFN-γ and TNF-α, or toll-
like receptor (TLR) ligands, where TLR and their ligands 
can reduce MSCs motility and promote their proliferation 
and differentiation.(145,146) Latest findings have showed 
that MSCs are immunosuppressive only when it is 
exposed to sufficiently high levels of pro-inflammatory 
cytokines (Figure 3).(147) In the presence of low levels of 
TNF-α and IFN-γ, MSCs may adopt a pro-inflammatory 
phenotype (MSC1) and enhance T cell responses, by 
secreting chemokines that recruit lymphocytes to the sites 
of inflammation (e.g., macrophage inflammatory protein 
1 alpha (MIP-1α), macrophage inflammatory protein-1β 
(MIP-1β), regulated on activation, normal T cell expressed 
and secreted (RANTES), C-X-C motif chemokine 
(CXCL)9, and CXCL10).(148) Under these conditions, 
inducible nitric oxide synthase (NOS) activity (for murine 
cells) and IDO activity (for human cells) are insufficient to 
suppress T lymphocyte proliferation (Figure 4).(147,149) 
The switch toward MSC1 phenotype or anti-inflammatory 
(MSC2) phenotype may also depend on MSC stimulation 
through TLRs expressed on their surface.(148) Polarization 
to MSC1 phenotype, important for early injury responses, 
can be influenced by lipopolysaccharide (LPS)-dependent 
trophic factors such as epidermal growth factor (EGF) and 
keratinocyte growth factor (KGF; also known as fibroblast 
growth factor (FGF)7) (88). During epithelial injury in 
a colitis model, the tissue-resident MSCs which sensed 
microbial molecules were repositioned near to epithelial 
progenitor cells and promoted epithelial proliferation by 
secreting prostaglandin E2 (PGE2) (89), which potentiates 
wingless/integrated (Wnt) signaling (90).
 A broad panel of molecular pathways is involved in 
MSC-mediated  immune  regulation,  including  interferon 
(IFN)-g  (91,92),  IL-1b  (93),  tumor  necrosis factor 
(TNF)-b1 (94-96), indoleamine-2,3-dioxygenase (IDO) 
(91,92,97), IL-6 (98,99), IL-10 (100,101), PGE2 (13), 
hepatocyte growth factor (HGF) (94),  TNF-a (102-104), 
nitric  oxide  (NO)  (105),  heme  oxygenase  (HO)-1 
(106), human leukocyte antigen (HLA)-G5 (107,108) and 
many other factors, some of which are still unidentified. 
Apparently, there is not a unique and hierarchically prevalent 
mechanism responsible for MSC immune regulation. 
Nonetheless, redundant panel of multiple pathways, some of 
them reciprocally activating, eventually leads to the anergy 
of immune effector cells regardless their antigen-mediated 
activation (13,91-122) and suggests that this property must 
be preserved for normal tissue homeostasis and interaction 
with immune effector cells infiltrating the tissues when 
inflammation happens.
 The role of MSCs as guardians of inflammation 
became more apparent as the events initiating inflammation 
have been defined in greater detail.(123-126) The events 
include both passive and active release from injured cells 
or macrophages of intracellular cytokines such as IL-1α that 
stimulate parenchymal cells to produce chemokines which 
recruit neutrophils; and classical activation of resident 
macrophages by damage-associated molecular patterns 
(DAMPs) or pathogen-associated molecular patterns 
(PAMPs) that interact with pattern recognition receptors to 
produce high levels of proinflammatory cytokines as well as 
reactive nitrogen and reactive oxygen species (ROS) which 
induce the acute phase response of inflammation.(127)
 The first reports describing the immunomodulatory 
activity of MSC were focused on their capacity to inhibit 
proliferation and function of T cells.(94) Subsequently, it 
became evident that suppression of T-cell activities was 
settled not only by a direct effect, but also through the 
inhibition  of  the  differentiation  and  function  of  cells 
involved   in   the   regulation   of   adaptive    immune 
responses.(128) Hence, MSC were shown to block 
the generation of functional antigen-presenting cells, 
including myeloid dendritic cells (DC) (101,129,130) and 
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activation of TLR4 (Figure 4), while double stranded RNA 
(dsRNA)-dependent activation of TLR3 may induce the 
polarization into MSC2 (Figure 3).(70) The balance between 
these opposing pathways may play role in promoting host 
defense on one hand and at the same time create a loop that 
prevents excessive tissue damage and promotes repair.(150)
 Critically ill patients often suffer from multiple organ 
failures such as lung, kidney, liver, or brain. Genomic, 
proteomic, and metabolomic approaches highlight common 
injury mechanisms leading to acute organ failure. This 
underlines the urgency to focus on therapeutic strategies 
that affect multiple injury pathways. The use of adult 
stem cells such as MSCs may represent a promising new 
therapeutic approach as increasing evidence proves that 
MSC can exert protective effects following injury through 
the release of promitotic, antiapoptotic, antiinflammatory, 
and immunomodulatory soluble factors. Furthermore, 
Figure 3. MSC-mediated immunosuppression. In the presence of high levels of IFN-γ and TNF-α or by activation of TLR3 by dsRNA, 
MSCs adopt an MSC2 phenotype. MSCs regulate proliferation, activation and effector function of a variety of immune cells, through cell-
to-cell contact or through producing of soluble factors including IDO, PGE2, NO, TGF-β, HGF, HO-1, IL-6, IL-10,TSG-6 and sHLA-G.
(145) INFGR: interferon-gamma receptor; TNFR: TNF receptor. (Adapted with permission from Springer).
they can   mitigate  metabolomic   and  oxidative  stress 
imbalance.(151)
 Both infection or non-infection causes can trigger 
organ damage through multiple signaling pathways such 
as inflammation, metabolomic disorders, oxidative stress, 
and apoptosis, performed during MSC therapeutic effects 
and lead to acute injury. MSC can exert pleiotropic 
therapeutic effects through the secretion of a wide array of 
soluble factors, which lead to: (1) antimicrobial activity, 
secretion of cathelicidin-related antimicrobial peptides and 
lipocalin, and monocytes and macrophages that increased 
phagocytosis; (2) anti-inflammatory activities, where M1 
macrophages will be switches into M2 phenotype, inhibition 
of T-lymphocyte and DC activation and increase in T 
regulatory cells; (3) reducing oxidative stress by increase in 
ATP cellular levels and decrease in ROS accumulation; (4) 
switch from a proapoptotic to a pro-mitotic phenotype.(151)
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Figure 4. Pro-inflammatory activity of MSCs. During the early phase of inflammation, in the presence of low levels of IFN-γ and TNF-α 
or by activation of TLR4 by low levels of LPS, MSCs may adopt a MSC1 phenotype.(145) MIF: migration inhibitory factor. (Adapted with 
permission from Springer).
MSCs Manage Macrophage Polarization
 The beneficial effects of cell-based therapy with 
MSCs are apparent in multiple preclinical injury models 
involving all the organs in Multiple Organ Dysfunction 
Syndrome (MODS). Attracted by signals from the injured 
and inflamed tissues, MSCs appear to migrate to the site 
of damage and secrete an array of soluble factors and/
or exosomes/microvesicles that suppress the injury. The 
preclinical evidence which provided the underlying rationale 
for several phase I/II clinical trials in Acute Respiratory 
Distress Syndrome (ARDS), Acute Kidney Injury (AKI), 
and stroke. Based on dependable preliminary results, further 
phase II and III trials are underway, the results of which 
are pending. However, no clinical studies are underway for 
Acute Liver Failure (ALF), Traumatic Brain Injury (TBI), 
sepsis, and MODS.(151) 
Macrophages are essential component in the orchestration 
and expression of innate immunity and adaptive 
immune responses. These cells play an important role in 
inflammation and host defense. Additionally, cells of the 
monocyte macrophage lineage fulfill homeostatic functions 
beyond defense.(152) These functions include tissue repair, 
wound healing, and regulation of metabolic activity.(153) 
Macrophages function was custom-fit to their residential 
tissue, as results of tissue-derived factors driven and the 
physiological environment.(152) Macrophages can acquire 
distinct functional phenotypes depend on the niche. The 
concept  of  macrophage  polarization was described for 
the first time in 1992 with the discovery that IL-4 potently 
enhances murine macrophage mannose receptor (CD206) 
activity.(154) Since then, two opposite and competing 
phenotypes, often referred to as classically activated 
macrophages (M1 macrophages) and alternatively activated 
macrophages (M2 macrophages), have been defined  and 
identified  in  several   physiological  settings.(155) Even 
though the classification of macrophages as M1/M2 just came 
after the classification of lymphocytes into Th1 and Th2, the 
Th1 and Th2-like responses are results of polarization of 
macrophages to M1 and M2 states, respectively. Moreover, 
M1/M2 polarization is not dependent on T cells, as has 
been demonstrated in Rag-1 knockout and other immune 
deficient mice.(156)
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 M1 macrophages are induced by TLR ligands (such 
as LPS) and IFN-g. They express higher levels of CD86 
and programmed death-ligand 1 (PD-L1).(157) M1 
macrophages are characterized by the increased microbicidal 
activity and produce several proinflammatory mediators, 
such as inducible NOS, TNF-b, IL-1b, IL-6, IL-12, and 
proteolytic enzymes.(158) They constitute the first line of 
defense against pathogens and promote Th1 polarization 
of CD4+ lymphocytes. Meanwhile, M2 macrophages are 
induced by Th2-type cytokines, such as IL-4 and IL-13. 
Tregs have also been implicated in induction process of M2 
polarization, possibly through IL-10.(159) M2-like cells 
have been potrayed in different pathological conditions 
such as infections by intracellular bacteria or virus, allergy, 
diabetes, and cancer.(155,160) They are characterized by 
the expression of CD163, CD206, arginase 1, Fizz1 (which 
is found in inflammatory zone 1), and CD36. In addition, 
they secrete anti-inflammatory cytokines, such as TGF-b, 
IL-1 receptor antagonist, and IL-10. M2 macrophages 
have an essential role in the suppression of Th1 immune 
responses and the enhancement of tissue remodeling and 
Th2 response.(161) Macrophages with intermediate or 
overlapping phenotypes have also been reported. For 
instance, adipose tissue macrophages from obese mice have 
a mixed profile, with upregulation of several M1 and M2 
gene transcripts.(162)
 Kim  and Hematti were the first to report that 
MSCs could polarize  macrophages from the classic 
proinflammatory M1 phenotype,  toward  the  anti-
inflammatory  M2 phenotype.(132) They found that 
macrophages co-cultured with MSCs consistently showed a 
high level expression of markers for M2 macrophages. The 
resulting macrophages produced high levels of IL-10 and 
low levels of IL-12 and TNF-b. Functionally, macrophages 
which co-cultured with MSCs showed a higher level of 
phagocytic activity (Figure 5).(163) Other studies showed 
that MSC-mediated polarization of M2 macrophages 
depends on the secretion of soluble factors, including PGE2, 
TSG-6, IL-6, IDO, and TGF-b1.(139,164,165)
 Through the prostaglandin receptors, MSCs can 
reprogram macrophages by cyclooxygenase-2 (COX2)
activity increasing and PGE2 releasing. This macrophage 
activated produces antiinflammatory IL-10. Thus, 
inflammatory signals activating MSCs to secrete anti-
inflammatory protein, TSG-6.(134) TSG-6  interacted 
through the CD44 receptor on resident macrophages to 
decrease zymosan/TLR2  signaling,  inducing a negative 
feedback  loop,  results beneficially  in  several  infllmation, 
based  disease  models.(166,167)
 Either monocyte differentiation or IL-10-secreting M2 
macrophages involved elevated IDO activity, and suppress 
T-cell proliferation in an IL-10-independent manner, thus 
amplifying the immunosuppressive effect generated by 
MSCs. By depleting monocytes from peripheral blood, 
another in vitro study found that monocytes were essential 
for MSC-induced Treg formation.(163) They suggest that 
MSCs promoted the survival of monocytes and induced 
differentiation toward M2 macrophages via unknown 
soluble factors. Then, M2 macrophages secreted high levels 
of IL-10 and chemokine C-C motif ligand (CCL)-18, which 
mediated the observed Treg induction.(167)
 MSCs support macrophages with stimulating signals 
that encouraged its polarization inti M2 phenotype, 
explained many of the beneficial effects observed with 
administration of MSCs in animal models for many diseases. 
Further studies on the molecular mechanisms involved in 
the interaction between MSCs and macrophages will devote 
to a better understanding of MSCs biology and the optimal 
use of MSCs in the clinical practice.(167)
Figure 5. MSCs and phagocytes closely interact during 
inflammatory responses.(163) KYN: kynurenine; MHC: major 
histocompatibility complex. (Adapted with permission from 
Nature Publishing Group).
MSCs Manage Wound Healing
 Chronic wound happens when there is a failure of 
injured skin to proceed through an orderly and timely process 
to produce anatomic and functional integrity. Causative 
factors include malnutrition and immunosuppression, 
and chronic wound is commonly seen as a consequence 
of diabetes mellitus and vascular compromise.(168) 
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MSCs Manage Vascular Homeostasis
Chronic wound is a common and severe complication of 
diabetes and are  associated  with significant  morbidity 
and mortality.(169) The impaired healing of diabetic 
wounds has been characterized by decreased production of 
chemokines (170), decreased angiogenesis (171), and an 
abnormal inflammatory response (172). Increasing evidence 
proposes that the persistent upregulation of inflammatory 
gene expression may plays role in the pathogenesis of the 
chronic diabetic wound through activation of inflammatory 
pathways.(173-175)
 MSCs have been shown to have a role in wound-
healing applications, including corrects diabetic wound 
healing in mice by accelerating epithelialization and 
increasing granulation tissue and angiogenesis.(176,177) 
However, the exact molecular mechanisms of this correction 
have not been fully characterized. Current understanding 
formulating two main mechanisms of MSCs in enhancing 
wound healing, which are by releasing bioactive mediators 
necessary for healing, together with cytokines and growth 
factors, and differentiating themselves into the cell types 
required for the healing process of the wound.(168)
 In addition to their differentiation ability, increasing 
evidence points to the ability of MSCs to secrete paracrine 
factors which modulate the local environment and stimulate 
wound healing.(178) Specifically, MSCs have been shown 
to significantly decrease the production of proinflammatory 
cytokines in the acute period when high levels can be 
deleterious to tissue and to upregulate them in the later 
regeneration phase.(179) Protein arrays have demonstrated 
that CM from MSC cultures contain various cytokines 
and chemokines such as IL-8, IL-6, TGF-b, and VEGF, 
all of which are essential to normal wound healing.(180) 
MSCs enhance the wound healing process by modulating 
angiogenesis and releasing proangiogenic factors 
such as VEGF and angiopoietin-1, reepithelialization, 
and granulation tissue formation. Other studies have 
demonstrated that intravenous (IV) injection in mice induced 
MSC trans-differentiation into keratinocytes, endothelial 
cells, and pericytes in cutaneous wounds. Application of 
human bone marrow MSCs to full thickness skin defects in 
mice in conjunction with IV MSC administration, can heal 
all wounds without a scar or retraction.(181)
 Several miRNAs have been found in skin tissue and 
are thought to have a crucial role in a broad range of biologic 
processes, including the regulation of innate and adaptive 
immune responses.(182-184) MiR-146a has been defined 
as one of the key regulatory molecules in the inflammatory 
response. It can be induced by different proinflammatory 
stimuli, such as IL-1β and TNF-α.(185,186) MiRNA-146a 
has also been known to negatively regulate the innate 
immune response by targeting and repressing IL-1 receptor-
associated kinase 1 (IRAK1) and TNFR-associated factor 6 
(TRAF6).(186) As two key adapter molecules of the nuclear 
factor (NF)-κB pathway, IRAK1 and TRAF6 increase NF-
κB activity, resulting in increased expression of the genes 
expressing IL-6 and IL-8 (187), which are key mediators 
of inflammation. Abnormal inflammation occurs in diabetic 
wounds and subsequent impairment in wound healing, in 
part was the responsibility of miR-146a, then MSC treatment 
for this diabetic wound-healing impairment is mediated by 
correction of abnormal miRNA-146a expression.(188)
Recently, there is increasing evidence indicating the 
relationship between tissue-specific stem/progenitor 
cells and vascular/perivascular niches (189,190) as well 
as the presence of multipotent stem cells of vascular 
origin (190-193). Sacchetti, et al., showed that CD146+ 
subendothelial stromal cells residing on the bone marrow 
sinusoidal wall not only self-renew and display vascular 
mural cell features but also form bone and establish the 
hematopoietic microenvironment.(40) Consequently, a 
hypothesis that blood vessels throughout the human body 
serve as a reservoir  of multipotent precursor cells has been 
formulated.(194,195)
 Using immunohistochemical assays and fluorescence-
activated cell sorting (FACS), three subpopulations of 
human blood-vessel-derived stem cells (hBVSC) has been 
successfully identified and purified from human blood 
vessels within human skeletal muscle, those are myogenic 
endothelial cells (MEC), pericytes, and adventitial cells 
(AC). These subpopulations each expressing a unique 
profile of cell surface antigens. Pericytes and ACs have 
also been isolated from several other human tissues such 
as fat and lung.(41,196-198) MECs, pericytes, and ACs 
all have common mesodermal multipotency and display 
typical MSC markers, suggesting their contributions to the 
heterogeneous MSCs entity.(197)
 Pericytes are commonly regarded as a structural 
component of small blood vessels that regulate vascular 
contractility, stability, and integrity.(199-202) Pericytes also 
modulate endothelial cell proliferation/vascular remodeling 
and are involved in specialized vascular functions including 
blood-brain barrier and renal tubulovesicular coordination 
as well as several pathological conditions.(203-208) 
However, this particular cell population has not been well 
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Figure 6. Potential translational applications of hBVSC 
subpopulations. The current translational applications of 
typical MSCs are summarized on the right. The current status of 
translational research for each hBVSC subset is outlined, whether 
the specific application has been tested or is presently under 
investigation.(199) PC: pericyte. (Adapted with permission from 
Hindawi).
defined in most of human organs because of the lack of 
representative cell marker. Alkaline phosphatase (ALP) is 
another marker used to typify pericytes in human skeletal 
muscle.(209,210) aSMA, on the other hand, can be detected 
in pericytes encircling arterioles and venules but not in 
those surrounding most capillaries.(41) Pericytes in situ 
also express classic MSC markers: CD44, CD73, CD90 and 
CD105.(41)
 Pericytes are involved in many different functions 
including maintenance of vascular contractility and 
permeability, control of vascular pressure, angiogenesis, 
immune defense, production of extracellular matrix 
(ECM) components, and keeping stability of vessels. In 
homeostasis, pericytes provide stabilization and nurturing 
signals to adjacent endothelial cells.(86,211,212) During 
angiogenic branching, pericytes are responsible for 
orchestrating new vessels to form a functionally efficient 
network.(213) Pericytes are thought to have regenerative 
properties of mesenchymal progenitor cells due to the 
ability to differentiate other cell types such as macrophages, 
myofibroblasts, osteoblasts, and adipocytes.(208,214) This 
capacity suggests the involvement of pericytes in vascular 
remodelling and vascular injury healing.(208,214)
 The capability to isolate subpopulations of hBVSCs 
marked  a  big  progress  to  understand  the  heterogeneous 
MSC entity as well as their vascular/perivascular niches 
(Figure 6). Purified MECs, pericytes, and ACs exhibited 
robust reparative/regenerative capacities in many injured/
defective tissues, often outperforming unfractionated 
MSCs.(199)
 MSCs exist in most adult tissues and are located 
near or within blood vessels. Although ‘‘perivascular’’ has 
been commonly used to describe such locations, increasing 
evidence points at the vessel wall as the exact location. 
Thus, ‘‘vascular stem cells (VSC)’’ is recommended as a 
more accurate term for MSCs. Two cell populations, called 
pericytes and adventitial progenitor cells (APC), likely 
were VSCs. The pericyte affirmation relies on the so-called 
pericyte-specific markers, though none of these markers is 
specific for pericyte. Moreover, pericytes appear to have a 
large differentiation capacity and too functionally diverse 
and sophisticated.   On the other hand, APCs are more naıve 
functionally and, therefore, more akin to being VSCs.(215)MSCs Manage Tissue Regeneration
Regenerative medicine becoming an enormous hopes 
for patients with severe diseases without any effective 
treatment. This great expectation of tissue renewal 
conception was first formulated in the study of hematosis 
over a century ago, facilitated by a self-sustaining pool of 
stem cells.(216) in the beginning this renewal concept was 
thought to be limited only for blood cells but now it has 
been proven that the maintenance and replenishment of 
the cellular composition in almost all tissues in our body, 
including skin and intestinal epithelium, liver, skeletal 
muscles, and myocardium, occur through the proliferation 
and differentiation of the corresponding tissue-specific stem 
cells.(217)
 Transplantation of MSCs stimulates the regeneration 
of tissues, including bone, skeletal muscles, myocardium, 
skin, liver, and peripheral nerves. This occurs owing to both 
the integration of transplanted MSCs into the recipient’s 
tissues and the secretory activity of these cells.(218) It was 
showed  that  transplanted MSCs integrate the endothelial 
lining of growing capillaries and the periendothelial space 
of  newly  formed  blood  vessels,  thereby  stabilizing 
them.(217) 
 Many studies identified secretion of proangiogenic 
factors, including Adrenomedullin (219), Cyr61 (220), and 
IL-1 (221),  and  left   ventricullar  remodelling attenuation 
was  observed  through  secretion  of   factors  promoting 
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either vasculogenesis  (222,223)  or  endothelial  tube 
formation (224). Other MSCs secreted factors promoted 
mobilization of cardiac stem/progenitor cells (219,225) 
or bone marrow-derived progenitor cells (226,227); 
specifically, secreted frizzled related protein (SFRP)2 
promoted MSC self-renewal and survival (228,229). 
Cardiomyocytes survival improvement was mediated by at 
least four different secreted factors.(219,230,231) Finally, 
anti-inflammatory factors like soluble TNFR1 (232) and 
TSG-6 (233) were identified. 
 MSCs are an important source of growth factors 
and cytokines, that participate in the regulation of tissue 
regeneration. Thus, MSCs produce factors in bone marrow 
that are necessary for the self-sustenance of hematopoietic 
stem  cells  and  keep  them  in  a  niche.  We   can  refer 
to such  factors as the SDF-1α, SCF, angiopoietin-1 and 
IL-7.(83)  It was established that MSCs produce angiogenic 
and neurotrophic growth factors, including VEGF,  HGF, 
basic fibroblast growth factor (bFGF), angiopoietin, nerve 
growth factor  (NGF),  brain-derived  neurotrophic  factor 
(BDNF), and   glial   cell   line-derived   neurotrophic  factor 
(GDNF).(234,235) The angiogenic growth factors produced 
by MSCs in the transplantation region stimulate the division 
of endothelial cells, their migration, and the formation of 
blood vessels. In addition, the factors produced by MSCs 
promote the mobilization of endothelial progenitors from 
the bone marrow, which participate in the formation of new 
blood vessels.(221,235) Simultaneously, the neurotrophic 
factors produced by MSCs stimulate both the growth and 
renewal of nerve endings.(234) Hence, MSCs can arbitrate 
the coordinated regulation of the growth of blood vessels 
and nerves during regeneration and remodeling of tissues 
(Figure 7). 
 Interestingly, the potential of MSCs to contribute 
to tissue repair has been found largely dependent on their 
secretory capacity rather than their differentiation capacity. 
Researches have mostly focused on the secretion of 
cytokines and growth factors by MSCs. However, recent 
data offers that the therapeutic effect of MSCs secretome 
can be partly due to secreted micro vesicles (MV), which 
can mirror the phenotype of their parent cells.(236)
 Cell-to-cell communication is required to insure proper 
coordination among different cell types within tissues. 
Cells may communicate by soluble factors (237), adhesion 
molecule-mediated cell-to-cell interactions including 
cytonemes that connect neighboring cells enabling ligand-
receptor-mediated transfer of surface-associated molecules, 
or by tunneling nanotubules that establish conduits between 
cells, allowing the transfer of not only surface molecules 
but also cytoplasmic components (238,239). Recent studies 
have suggested that cells may also communicate by circular 
membrane fragments, namely MV.(240) This concept is 
based on the founding that MVs are released from a given 
cell type may interact via specific receptor ligands with 
other cells, leading to target cell stimulation directly or by 
transferring surface receptors.(241,242) This implicates 
that MVs interact only with target cells that specifically 
recognize rather than just with any cell present in the 
microenvironment.(243)
 The finding of paracrine features of MSCs really open 
a new dimension to the therapeutic applications of MSCs 
in regenerative medicine, and many limitation and safety 
concerns in MSCs transplantation could be mitigated.(244) 
recent studies suggested a bidirectional exchange of genetic 
information between stem and injured cells, and this gene 
products transfer from injured cells to stem cells explain 
how the stem cell changes functional and phenotypic 
without the need of transdifferentiation into tissue cells. On 
the contrary, transfer of gene products from stem cells may 
reprogram injured cells to repair damaged tissues.(245)
 MSCs and stem/pericytes cells could be seen as 
sensory,   highly   receptive  to   local biologic  information; 
synthetic, capable of producing biomolecules in response 
to the received information; and secretory, capable of 
fabricating and delivering those biomolecules;  units 
characterized by their innate therapeutic potential.(148) 
These units or cells have acquired these unique capabilities 
through evolution and provide the organism with unique, 
highly adaptive, survival characteristics. In the analogy to a 
computer proposed by Hariri, these stem and progenitor cells 
have a design in which the nucleus houses the operational 
software, resident in the DNA of the chromosomes, at the 
Figure 7. Hypothetic scheme showing the interaction of MSCs 
with axons, endothelial cells, leukocytes, and tissue-specific 
stem cells.(217) (Adapted with permission from Park-media).
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core of a complex processor and complex information 
transferring apparatus within the cell cytoplasm.(246)
 Thus, the therapeutic output of cell-based therapies 
relies both on the docking or sensing and on the cellular 
output in the form of secreted factors (247), which exert 
their effects in our genomically controlled endocrine or 
paracrine regeneration/repair ability. By the time humans 
reach the age of 40-50 years, this regenerative and repair 
potential is greatly diminished and accounts for “late-onset” 
diseases or tissue dysfunction. The medical challenge is 
to find how to optimize the remaining innate regenerative 
potential and to understand how to supplement these unique 
functionalities.(38)
 On the assumption that MSC is undoubtedly roles 
as the managers of site-specific tissue regeneration, their 
presence, number, proper activation, coordinated and 
dynamic function surely have a profound impact on injury 
and disease progression. Thus, the medicinal activity of 
MSC is dependent on the tissue management and site of 
injury aspects, with respect to the therapeutic capacity of 
either endogenous or exogenously supplied MSCs. This 
infers that MSCs are intrinsically curative and that their 
therapeutic effectiveness solely depends on the “when, 
where, and how” of their delivery or presentation at sites of 
injury, disease, or regeneration.(248)
The multipotent MSC, now renamed the medicinal signaling 
cell, predominantly raises from pericytes released from 
broken and inflamed blood vessels and seems to function 
as both an immunomodulatory and a regeneration mediator. 
MSCs are being tested for their management capabilities 
to produce therapeutic outcomes in more than 480 clinical 
trials for a wide range of clinical conditions. Local MSCs 
function by managing the body’s primary repair and 
regeneration activities. MSCs can be obtained from many 
tissues in human body, either allogeneic or autologous origin, 
and have a highly plasticity features that allows MSCs to 
transform into many type of cells such as their capacity to 
differentiate into adipocytes, osteocytes, chondrocytes, and 
neuronal/glial cells. Together with its paracrine features, 
MSC-based therapy has the potential to change how health 
care is delivered. These medicinal cells have a capability of 
sensing their surroundings, and with their complex signaling 
circuitry, they organize site-specific regenerative responses 
smartly as if these therapeutic cells were well-programmed 
modern computers. Given these facts, it appears that we 
Conclusion
are entering a new age of cellular medicine. The innate 
regenerative capacity of almost every host tissue has never 
been properly managed and MSCs appear to be assisting the 
host tissue to maximize its intrinsic regenerative capacity. 
The Medicine of Tomorrow may be the management of 
MSCs to optimize the body’s very powerful and ever- 
changing intrinsic regenerative potential. The reason for 
reviewing the above is to emphasize the emerging theme 
that MSCs appear to be assisting the host tissue to maximize 
its intrinsic regenerative capacity. The local management of 
the immune cells and the tissue specific progenitors appears 
to be accomplished by very few, locally situated, and short-
lived MSCs. This innate regenerative capacity of almost 
every host tissue has never been properly managed except, 
perhaps, in orthopedics where the vigorous regenerative 
and repair capacity of bone (maybe through local MSCs) is 
managed by orthopedic physician interface. The Medicine 
of Tomorrow may be the management of MSCs to optimize 
the body’s very powerful and ever changing intrinsic 
regenerative potential.
1. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, 
Keiliss-Borok IV. Stromal cells responsible for transferring the 
microenvironment of the hemopoietic tissues: cloning in vitro and 
retransplantation in vivo. Transplantation. 1974; 17: 331-40.
2. Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, 
et al. Isolation and perivascular localization of mesenchymal stem 
cells from mouse brain. Neurosurgery. 2010; 67: 711-20.
3. Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, Sempoux C, et 
al. Adult-derived human liver mesenchymal-like cells as a potential 
progenitor reservoir of hepatocytes? Cell Transplant. 2007; 16: 717-
28.
4. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, et al. 
Evidence for tissue-resident mesenchymal stem cells in human 
adult lung from studies of transplanted allografts. J Clin Invest. 
2007; 117: 989-96.
5. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et 
al. Mesenchymal stem cells in the Wharton’s jelly of the human 
umbilical cord. Stem Cells. 2004; 22: 1330-7.
6. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et 
al. Human adipose tissue is a source of multipotent stem cells. Mol 
Biol Cell. 2002; 13: 4279-95.
7. Lina Y, Wijaya A. Novel sources of fetal stem cells for future 
regenerative medicine. Indones Biomed J. 2012; 4: 3-11.
8. Lina Y, Wijaya A. Adipose-derived stem cells for future regenerative 
system medicine. Indones Biomed J. 2012; 4: 59-72.
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca 
JD, et al. Multilineage potential of adult human mesenchymal stem 
cells. Science. 1999; 284: 143-7.
10. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, 
Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells 
derived from adult marrow. Nature. 2002; 418: 41-9.
References
84
The Indonesian Biomedical Journal, Vol.8, No.2, August 2016, p.71-90 Print ISSN: 2085-3297, Online ISSN: 2355-9179
32. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo 
identity of mesenchymal stem cells. Stem Cells. 2008; 26: 2287-99.
33. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal 
stem cells: nature, biology, and potential applications. Stem Cells. 
2001; 19: 180-92.
34. Shehadah A, Chen J, Pal A, He S, Zeitlin A, Cui X, et al. Human 
placenta-derived adherent cell treatment of experimental stroke 
promotes functional recovery after stroke in young adult and older 
rats. PLoS One. 2014; 9: e86621.
35. Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn 
FO, et al. Adventitial delivery of an allogeneic bone marrow-
derived adherent stem cell in acute myocardial infarction: phase I 
clinical study. Circ Res. 2012; 110: 304-11.
36. See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, 
et al. Therapeutic effects of human STRO-3-selected mesenchymal 
precursor cells and their soluble factors in experimental myocardial 
ischemia. J Cell Mol Med. 2011; 15: 2117-29.
37. Gir P, Oni G, Brown SA, Mojallal A, Rohrich RJ. Human adipose 
stem cells: current clinical applications. Plast Reconstr Surg. 2012; 
129: 1277-90.
38. Caplan AI, Hariri R. Body management: mesenchymal stem cells 
control the internal regenerator. Sem Cell Transl Med. 2015; 4: 695-
701.
39. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008; 3: 229-30.
40. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio 
I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids 
can organize a hematopoietic microenvironment. Cell. 2007; 131: 
324-36.
41. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A 
perivascular origin for mesenchymal stem cells in multiple human 
organs. Cell Stem Cell. 2008; 3: 301-13.
42. Penn MS, Anwaruddin S, Nair R, Ellis S. From mice to men: 
commonalities in physiology for stem cell-based cardiac repair. J 
Am Coll Cardiol. 2009; 54: 2287-9.
43. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by 
human marrow-derived mesenchymal progenitor cells in vitro: 
effects of dexamethasone and IL-1alpha. J Cell Physiol. 1996; 166: 
585-92.
44. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem 
cells reside in virtually all post-natal organs and tissues. J Cell Sci. 
2006; 119:  2204-13.
45. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk 
NM. Identification of mesenchymal stem/progenitor cells in human 
first-trimester fetal blood, liver, and bone marrow. Blood. 2001; 98: 
2396-402. 
46. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and 
engraftment, cell-targeting strategies, and immune modulation. 
Stem Cells Int. 2013; 2013: 732742.
47. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of 
inflammation. Annu Rev Pathol. 2011; 6: 457-78. 
48. Li Y, Chen J, Chen XG, Wang L, Gautam SC, Xu YX, et al. Human 
marrow stromal cell therapy for stroke in rat: neurotrophins and 
functional recovery. Neurology. 2002; 59: 514-23.
49. Siegel G, Krause P, Wöhrle S, Nowak P, Ayturan M, Kluba T, 
et al. Bone marrow-derived human mesenchymal stem cells 
express cardiomyogenic proteins but do not exhibit functional 
cardiomyogenic differentiation potential. Stem Cells Dev. 2012; 21: 
2457-70.
50. van Koppen A, Joles JA, van Balkom BW, Lim SK, de Kleijn D, 
Giles RH, et al. Human embryonic mesenchymal stem cell-derived 
conditioned medium rescues kidney function in rats with established 
chronic kidney disease. PLoS One. 2012; 7: e38746.
11. Mafi R, Hindocha S, Mafi P, Griffin M, Khan WS. Sources of 
adult mesenchymal stem cells applicable for musculoskeletal 
applications: a systematic review of the literature. Open Orthop J. 
2011; 5 (Suppl 2): 242-8.
12. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, 
Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells 
restore cardiac function in chronic ischemic cardiomyopathy via 
trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009; 
106: 14022-7.
13. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood. 2005; 105: 1815-22.
14. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. 
J Cell Biochem. 2006; 98: 1076-84.
15. Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B. 
Preconditioning enhances the paracrine effect of mesenchymal stem 
cells in preventing oxygen-induced neonatal lung injury in rats. 
Stem Cells Dev. 2012; 21: 2789-97.
16. Du Z, Wei C, Cheng K, Han B, Yan J, Zhang M, et al. Mesenchymal 
stem cell-conditioned medium reduces liver injury and enhances 
regeneration in reduced-size rat liver transplantation. J Surg Res. 
2013; 183: 907-15. 
17. Lavoie JR, Rosu-Myles M. Uncovering the secretes of mesenchymal 
stem cells. Biochimie. 2013; 95: 2212-21.
18. Pittenger MF, Le Blanc K, Phinney DG, Chan JK. MSCs: scientific 
support for multiple therapies. Stem Cell Int. 2015; 2015: 280572.
19. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini 
F, Krause D, et al. Minimal criteria for defining multipotent 
mesenchymal stromal cells: The International Society for Cellular 
Therapy position statement. Cytotherapy. 2006; 8: 315-7.
20. Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B, et al. 
Therapeutic applications of mesenchymal stromal cells. Semin Cell 
Dev Biol. 2007; 18: 846-58.
21. Bluguermann C, Wu L, Petrigliano F, McAllister D, Miriuka S, 
Evseenko DA. Novel aspects of parenchymal-mesenchymal 
interactions: from cell types to molecules and beyond. Cell Biochem 
Funct. 2013; 31: 271-80.
22. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit 
of intravenous administration of bone marrow stromal cells after 
cerebral ischemia in rats. Stroke. 2001; 32: 1005-11.
23. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski 
N, et al. Mesenchymal stem cell engraftment in lung is enhanced in 
response to bleomycin exposure and ameliorates its fibrotic effects. 
Proc Natl Acad Sci USA. 2003; 100: 8407-11.
24. Park KS, Jung KH, Kim SH, Kim KS, Choi MR, Kim Y, et al. 
Functional expression of ion channels in mesenchymal stem cells 
derived from umbilical cord vein. Stem Cells. 2007; 25: 2044-52.
25. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al. Bone 
marrow-derived mesenchymal stem cells in repair of the injured 
lung. Am J Respir Cell Mol Biol. 2005; 33: 145-52.
26. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue 
regeneration. Regen Med. 2010; 5: 121-43.
27. Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow 
mesenchymal stem cells: agents of immunomodulation and 
neuroprotection. Curr Stem Cell Res Ther. 2011; 6: 63-8.
28. Dittmer J, Leyh B. Paracrine effects of stem cells in wound healing 
and cancer progression. Int J Oncol. 2014; 44: 1789-98.
29. Caplan AI. What’s in a name? Tissue Eng Part A. 2010; 16: 2415-7.
30. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 
2011; 9: 11-5.
31. Caplan AI. MSCs: the new medicine. In: Vertes A, editor. Stem 
Cells in Regenerative Medicine: Science, Regulation and Business 
Strategies. New York: John Wiley & Sons; 2016. p.415-22.
 85
MSCs Manage Endogenous Tissue Regeneration (Meiliana A, et al.)Indones  Biomed J. 2016; 8(2): 71-90 DOI: 10.18585/inabj.v8i2.211
51. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles 
AW, et al. Mesenchymal stem cell-derived molecules directly 
modulate hepatocellular death and regeneration in vitro and in vivo. 
Hepatology. 2008; 47: 1634-43.
52. Caplan AI. Why are MSCs therapeutic? New data: new insight. J 
Pathol. 2009; 217: 318-24.
53. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic 
tissues. Science.1997; 276: 71-4.
54. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. 
Vasculotropic, paracrine actions of infused mesenchymal stem 
cells are important to the recovery from acute kidney injury. Am J 
Physiol Renal Physiol. 2007; 292: F1626-35. 
55. Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine 
signaling and differentiation during cutaneous wound repair. Exp 
Cell Res. 2010; 316: 2213-9.
56. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt 
HJ, et al. Mesenchymal stem cells are short-lived and do not migrate 
beyond the lungs after intravenous infusion. Front Immunol. 2012; 
3: 297. 
57. Liu XB, Chen H, Chen HQ, Zhu MF, Hu XY, Wang YP, et al. 
Angiopoietin-1 preconditioning enhances survival and functional 
recovery of mesenchymal stem cell transplantation. J Zhejiang Univ 
Sci B. 2012; 13: 616-23.
58. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn J. The life and fate of 
mesenchymal stem cells. Front Immunol. 2014; 5: 148.
59. Singer M. The trophic quality of the neuron: some theoretical 
considerations. Prog Brain Res. 1964; 13: 228-32.
60. Singer M. The trophic quality of the neuron: some theoretical 
considerations. In: Singer M, Schade JP, editors. Progress in Brain 
Research. Amsterdam: Elsevier; 1964.
61. Singer M. Neurotrophic control of limb regeneration in the newt. Ann 
NY Acad Sci. 1974; 228: 308-22.
62. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. 
Mesenchymal stem cells modified with akt prevent remodeling and 
restore performance of infarcted hearts. Nature Med. 2003; 9: 1195-
201.
63. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, et al. 
Autologous mesenchymal stem cell transplantation induce VEGF 
and neovascularization in ischemic myocardium. Regul Pept. 2004; 
117: 3-10.
64. Sinsicalco D, Sullo N, Maione S, Rossi F , D’ A gostino B. Stem cell 
therapy: the great promise in lung disease. Ther Adv Respir Dis. 
2008; 2: 173-7.
65. Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, et al. The 
sensitivity of human mesenchymal stem cells to ionizing radiation. 
Int J Radiat Oncol Biol Phys. 2006; 66: 244 -53.
66. Bai L, Caplan AI, Lennon DL, Miller RH. Human mesenchymal stem 
cell signals regulate neural stem cell fate. Neurochem Res. 2007; 
32: 353-62.
67. Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic 
differential of human adipose-derived adult stem cells by bone 
morphogenetic protein 6. Arthrit Rheum. 2006; 54: 1222-32.
68. da Silva Meirelles L, Sand TT, Harman RJ, Lennon DP, Caplan AI. 
MSC frequency correlates with blood vessel density in equine 
adipose tissue. Tiss Eng A. 2009; 15: 221-9.
69. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, et al. 
The meaning, the sense and the significance: translating the science 
of mesenchymal stem cells into medicine. Nat Med. 2013; 19: 35-
42.
70. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. 
Blood. 2011; 117: 5281-8.
71. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived 
mesenchymal stem cells facilitate engineering of long-lasting 
functional vasculature. Blood. 2008; 111: 4551-8.
72. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, 
Oettgen P, et al. Engineering robust and functional vascular networks 
in vivo with human adult and cord blood-derived progenitor cells. 
Circ Res. 2008; 103: 194-202.
73. Moioli EK, Clark PA, Chen M, Dennis JE, Erickson HP, Gerson SL, 
et al. Synergistic actions of hematopoietic and mesenchymal stem/
progenitor cells in vascularizing bioengineered tissues. PLoS ONE. 
2008; 3: e3922
74. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A 
perivascular origin for mesenchymal stem cells in multiple human 
organs. Cell Stem Cell. 2008; 3: 301-13.
75. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin 
MG. An isoform of decorin is a resistin receptor on the surface of 
adipose progenitor cells. Cell Stem Cell. 2011; 9: 74-86.
76. Berg RD. The indigenous gastrointestinal microflora. Trends 
Microbiol. 1996; 4: 430-5.
77. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev 
Microbiol . 1977; 31: 107-33.
78. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual 
anti-inflammatory and pro-resolution lipid mediators. Nat Rev 
Immunol. 2008; 8: 349-61.
79. Gordon S, Martinez FO. Alternative activation of macrophages: 
mechanism and functions. Immunity. 2010; 32: 593-604.
80. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and 
intestinal inflammation. Annu Rev Immunol. 2009; 27: 313-38.
81. Wan YY. Regulatory T cells: immune suppression and beyond. Cell 
Mol Immunol. 2010; 7: 204-10.
82. Bianco P, Sacchetti B, Riminucci M. Osteoprogenitors and the 
hematopoietic microenvironment. Best Pract Res Clin Haematol. 
2011; 24: 37-47.
83. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur 
BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells 
form a unique bone marrow niche. Nature. 2010; 466: 829-34.
84. Ganz T. Epithelia: not just physical barriers. Proc Natl Acad Sci USA. 
2002; 99: 3357-8.
85. Signore M, Cerio AM, Boe A, Pagliuca A, Zaottini V, Schiavoni I, 
et al. Identity and ranking of colonic mesenchymal stromal cells. J 
Cell Physiol.  2012; 227: 3291-300. 
86. Diaz-Flores L, Gutiérrez R, Madrid JF, Varela H, Valladares F, Acosta 
E, et al. Pericytes: Morphofunction, interactions and pathology in a 
quiescent and activated mesenchymal cell niche. Histol Histopathol. 
2009; 24: 909-69.
87. Brittan M, Wright NA. Stem cell in gastrointestinal structure and 
neoplastic development. Gut. 2004; 53: 899-910. 
88. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms 
involved in the therapeutic properties of mesenchymal stem cells. 
Cytokine Growth Factor Rev. 2009; 20: 419-27.
89. Brown SL, Riehl TE, Walker MR, Geske MJ, Doherty JM, Stenson 
WF, et al.  Myd88-dependent positioning of Ptgs2-expressing 
stromal cells maintains colonic epithelial proliferation during 
injury. J Clin Invest. 2007; 117: 258-69. 
90. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper 
CL, et al. Genetic interaction of PGE2 and Wnt signaling regulates 
developmental specification of stem cells and regeneration. Cell. 
2009; 136: 1136-47.
91. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et 
al. Role for interferon-gamma in the immunomodulatory activity 
of human bone marrow mesenchymal stem cells. Stem Cells. 2006; 
24: 386-98.
86
The Indonesian Biomedical Journal, Vol.8, No.2, August 2016, p.71-90 Print ISSN: 2085-3297, Online ISSN: 2355-9179
92. Krampera M, Sartoris S, Liotta F, Pasini A, Angeli R, Cosmi L, et al. 
Immune regulation by mesenchymal stem cells derived from adult 
spleen and thymus. Stem Cells Dev. 2007; 16: 797-810.
93. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem 
cells require monocyte-mediated activation to suppress alloreactive 
T cells. Exp Hematol. 2005; 33: 928-34.
94. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, 
Matteucci P, et al. Human bone marrow stromal cells suppress 
T-lymphocyte proliferation induced by cellular or nonspecific 
mitogenic stimuli. Blood. 2002; 99: 3838-43.
95. Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T. The 
immunogenicity and immunomodulatory function of osteogenic 
cells differentiated from mesenchymal stem cells. J Immunol. 2006; 
176: 2864-71.
96. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. 
Suppression of allogeneic T-cell proliferation by human marrow 
stromal cells: implications in transplantation. Transplantation. 
2003; 75: 389-97.
97. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo 
D. Human bone marrow stromal cells inhibit allogeneic T-cell 
responses by indoleamine 2,3-dioxygenase mediated tryptophan 
degradation. Blood. 2004; 103: 4619-21.
98. Xu G, Zhang Y, Zhang L, Ren G, Shi Y. The role of IL-6 in inhibition 
of lymphocyte apoptosis by mesenchymal stem cells. Biochem 
Biophys Res Commun. 2007; 361: 745-50.
99. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony 
C, Apparailly F, et al. Mesenchymal stem cells inhibit the 
differentiation of dendritic cells through an interleukin-6-dependent 
mechanism. Stem Cells. 2007; 25: 2025-32.
100. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of 
mesenchymal stem cells on differentiation, maturation, and function 
of human monocyte-derived dendritic cells. Stem Cells Dev. 2004; 
13: 263-71.
101. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human 
mesenchymal stem cells inhibit differentiation and function of 
monocyte-derived dendritic cells. Blood. 2005; 105: 4120-6.
102. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, 
et al. Human mesenchymal stem cells alter antigen-presenting cell 
maturation and induce T-cell unresponsiveness. Blood. 2005; 105: 
2214-9.
103. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, 
Beggs KJ, Simonetti DW, et al. T cell responses to allogeneic 
human mesenchymal stem cells: immunogenicity, tolerance, and 
suppression. J Biomed Sci. 2005; 12: 47-57.
104. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-
like activity of mesenchymal stem cells: functional discrimination 
between cellular responses to alloantigens and recall antigens. J 
Immunol. 2003; 171: 3426-34.
105. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric 
oxide plays a critical role in suppression of T-cell proliferation by 
mesenchymal stem cells. Blood. 2007; 109: 228-34.
106. Cbannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, et 
al. A role for heme oxygenase-1 in the immunosuppressive effect 
of adult rat and human mesenchymal stem cells. Blood. 2007; 110: 
3691-4.
107. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human 
leukocyte antigen-G5 secretion by human mesenchymal stem cells 
is required to suppress T-lymphocyte and natural killer function and 
to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 
2008; 26: 212-22.
108. Oh I, Ozaki K, Sato K, Meguro A, Tatara R, Hatanaka K, et al. 
Interferon-gamma and NF-kappaB mediate nitric oxide production 
by mesenchymal stromal cells. Biochem Biophys Res Commun. 
2007; 355: 956-62.
109. Haniffa MA, Collin MP, Buckley CD, Dazzi F. Mesenchymal stem 
cells: the fibroblasts’ new clothes? Haematologica. 2009; 94: 258-
63.
110. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. 
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte 
cultures and mitogenic responses independently of the major 
histocompatibility complex. Scand J Immunol. 2003; 57: 11-20.
111. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et 
al. Bone marrow mesenchymal stem cells inhibit the response of 
naive and memory antigen-specific T cells to their cognate peptide. 
Blood. 2003; 101: 3722-9.
112. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow 
mesenchymal stem cells induce division arrest anergy of activated 
T cells. Blood. 2005; 105: 2821-7.
113. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. 
Mesenchymal stem cells inhibit human Th17 cell differentiation 
and function and induce a T regulatory cell phenotype. J Immunol. 
2010; 185: 302-12.
114. Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V. 
Reciprocal interactions between human mesenchymal stem cells 
and gammadelta T cells or invariant natural killer T cells. Stem 
Cells. 2009; 27: 693-702.
115. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti 
F, et al. Human mesenchymal stem cells modulate B cell functions. 
Blood. 2006; 107: 367-72.
116. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. 
Mesenchymal stem cell-natural killer cell interactions: evidence 
that activated NK cells are capable of killing MSCs, whereas MSCs 
can inhibit IL-2-induced NK-cell proliferation. Blood. 2006; 107: 
1484-90.
117. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi 
F. Mesenchymal stem cells inhibit dendritic cell differentiation and 
function by preventing entry into the cell cycle. Transplantation. 
2007; 83: 71-6.
118. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, 
Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil 
apoptosis: a model for neutrophil preservation in the bone marrow 
niche. Stem Cells. 2008; 26: 151-62.
119. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et 
al. Immunomodulative effect of human adipose tissue-derived adult 
stromal cells: comparison with bone marrow mesenchymal stem 
cells. Br J Haematol. 2005; 129: 118-29.
120. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. 
HLA expression and immunologic properties of differentiated and 
undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31: 
890-6.
121. Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect 
of mesenchymal stem cells is a fundamental property shared by all 
stromal cells. J Immunol. 2007; 179: 2824-31.
122. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, 
et al. Adult human fibroblasts are potent immunoregulatory cells 
and functionally equivalent to mesenchymal stem cells. J Immunol. 
2007; 179: 1595-604.
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